Quality Care Recommendations: Stage IB – IIIA Non-Small Cell lung Cancer (NSCLC)

You must have an ACCC account in order to register for this course.

If You DO NOT Have An ACCC Account:

To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page.
- ACCC members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page, where you can view and update your information.
- OSS at ACCC Members: Please use your state society login credentials.
- Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page, where you can view and update your information. Click “Change” to add your Areas of Concentration, then save your information.
Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link.
The green box in the upper right corner of this page will indicate “You are registered!” for this course. Congratulations!

If You Have An ACCC Account:

Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button.
You will be automatically redirected back to this webinar page, and the green box in the upper right corner will say that “You are registered!” for this course. Congratulations!

PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar.

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this webinar . For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.

Join ACCC and guest speakers, Drs. Brendon Stiles and Percy Lee, to learn about a new resource developed by expert stakeholders that incorporates evidence-based guidance on best practice in stage IB/IIIA NSCLC. The resource addresses recommendations in four core components: care coordination and patient education, diagnosis and initial management, treatment planning, and survivorship, and can be used by cancer programs to promote ideal care to patients with stage IB/IIIA NSCLC.

Percy Lee, MD

Professor and Vice-Chair of Clinical Research, Medical Director for Orange County and Coastal Regions in the Department of Radiation Oncology

City of Hope National Medical Center

Dr. Percy Lee is professor and vice-chair of Clinical Research and medical director for Orange County and Coastal Regions in the Department of Radiation Oncology at City of Hope National Medical Center. Dr. Lee has an international reputation in the treatment of thoracic and gastrointestinal malignancies. His research interests include applying novel technologies, such as MRI-guided radiation therapy, in the clinic and he led the clinical implementation of MRI-guided radiation therapy program at the University of California Los Angeles (UCLA), only the third site in the world with this innovation. In addition, he is a clinical trialist who is interested in combining novel radiation therapy approaches with new drugs to achieve improved outcomes in thoracic malignancies.

Dr. Lee began his career at UCLA, where he rose to the rank of professor and vice chair of Education for the Department of Radiation. There, he also served as chief of Thoracic Radiation Oncology, Residency Training Program director, and director of the Stereotactic Body Radiation Therapy Program. Subsequently, Dr. Lee served as section chief of Thoracic Radiation Oncology at MD Anderson Cancer Center from 2019-2022. In addition to these posts, Dr. Lee has served on various leadership roles within national organizations such as the American Society for Radiation Oncology, the American Board of Radiology, American Radium Society, and the Radiosurgery Society.

Dr. Lee earned his bachelor’s degree in biomedical engineering from Johns Hopkins University in Baltimore, Md. and his medical degree from Harvard Medical School in Boston, Mass. He completed his clinical internship in internal medicine at Massachusetts General Hospital, his residency in radiation oncology at Stanford University in California, and is board certified in Radiology. Dr. Lee was born and raised in Taipei, Taiwan until the age of 9, and still has family throughout the island.

Brendon Stiles, MD

Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic & Vascular Surgery, Associate Director, Surgical Services

Albert Einstein College of Medicine

Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic & Vascular Surgery at Montefiore-Einstein. Dr. Stiles is also the Associate Director for Surgical Services in the Montefiore-Einstein Cancer Center. Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.

Dr. Stiles is also heavily involved with translational and basic research. Translationally, Dr. Stiles is interested in neoadjuvant immunotherapy and in predicting and augmenting response to immunotherapy. In the laboratory, he has been funded by the AATS, TSF, the Lung Cancer Research Foundation, the DOD CDMRP Lung Cancer Research Program, and the Mark Foundation.

Dr. Stiles' laboratory currently investigates the protein ART1, an extracellular mono-ADP-ribosyltransferase. Recently, Dr. Stiles and his team discovered that ART1 may play an important role in one mechanism of resistance in lung cancers. ART1 mono-ADP-ribosylates the P2X7 receptor (P2X7R) on immune cells, which ultimately causes NAD-induced cell death (NICD) in T cells, macrophages, and dendritic cells. They found ART1 to be highly expressed in multiple human non-small cell lung cancer cell lines and in the majority of human lung adenocarcinomas they sampled. ART1 expression allows cancers to blunt the immune response against them. Indeed, they found that inhibiting ART1 with a therapeutic monoclonal antibody in mouse models of lung cancer caused a dramatic reduction of tumor burden and an enrichment of immune cells in the tumor.

Current efforts are underway to better understand regulation of ART1 expression, to identify more targets of extracellular mono-ADP-ribosylation, and to refine pre-clincal models to test their therapeutic antibody targeting ART1.

Joseph Kim, MD, MBA, MPH (Moderator)

XAF Solutions

Dr. Joseph Kim is President of Xaf Solutions, a consultancy focused on improving team-based care. He is a certified professional in healthcare quality and holds degrees a BS in engineering from MIT, an MD from the University of Arkansas College of Medicine, an MPH from UMass Amherst School of Public Health, and an MBA from St. Joseph’s University.